EUCTR2004-003435-31-IT进行中（未招募）不适用
A Phase III Study of the Efficacy and Safety of AlzhemedTM as Add-on Therapy in Mild to Moderate Alzheimer s Disease Patients
EUROCHEM INC.0 个研究点开始时间: 2005年12月15日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A Phase III Study of the Efficacy and Safety of Alzhemed™ as Add-on Therapy in Mild to Moderate Alzheimer's Disease Patients.EUCTR2004-003435-31-SEeurochem Inc.930
进行中（未招募）
不适用
A Phase III Study of the Efficacy and Safety of Alzhemed™ as Add-on Therapy in Mild to Moderate Alzheimer's Disease Patients.EUCTR2004-003435-31-BEeurochem Inc.930
进行中（未招募）
1 期
A Phase III Study of the Efficacy and Safety of Alzhemed™ as Add-on Therapy in Mild to Moderate Alzheimer's Disease Patients.Alzheimer’s Disease (AD) is an irreversible, progressive neuro-degenartive disorder, characterized by gradual cognitive deficits associated with abnormal behaviour, personality changes, and which ultimately leads to dementia.Cerebral amyloid angiopathy (CAA) has also been found to be particularly common in Alzheimer patients.MedDRA version: 8.1Level: LLTClassification code 10001896Term: Alzheimer's diseaseEUCTR2004-003435-31-GBeurochem Inc.930
进行中（未招募）
不适用
A Phase III Study of the Efficacy and Safety of Alzhemed™ as Add-on Therapy in Mild to Moderate Alzheimer's Disease Patients.Alzheimer’s Disease (AD) is an irreversible, progressive neuro-degenartive disorder, characterized by gradual cognitive deficits associated with abnormal behaviour, personality changes, and which ultimately leads to dementia.Cerebral amyloid angiopathy (CAA) has also been found to be particularly common in Alzheimer patients.MedDRA version: 8.1Level: LLTClassification code 10001896Term: Alzheimer's diseaseEUCTR2004-003435-31-DEeurochem Inc.930
进行中（未招募）
不适用
A study of Aleglitazar in Patients with Stable Cardiovascular disease and Glucose AbnormalitiesStable Cardiovascular Disease and Diabetes Mellitus Type 2 or Pre-diabetesMedDRA version: 14.1Level: LLTClassification code 10007648Term: Cardiovascular disease, unspecifiedSystem Organ Class: 100000004849MedDRA version: 14.1Level: LLTClassification code 10036481Term: Pre-diabetesSystem Organ Class: 100000004861EUCTR2012-000671-16-ITF. HOFFMANN - LA ROCHE LTD.19,000